不同甲基化修饰在心血管疾病中的作用
Yuan Lin1,2,3,4, Jennifer Wang5, Xin Liu1,2,3
1State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), College of Pharmacy, and Department of Cardiology, the Second Affiliated Hospital, Harbin Medical University, Harbin, 150081, China.
Frontiers of medicine
|December 26, 2025
概括
表观遗传甲基化修饰,包括DNA,蛋白质和RNAN6-甲基氨酸 (m6A) 变化,对于心血管疾病的发展至关重要. 了解这些表观遗传机制为心脏病提供了新的治疗点.
科学领域:
- 分子生物学分子生物学
- 心脏病学 心脏病学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 心血管疾病 (CVD) 是全球死亡率和残疾的主要原因.
- 有效的预防和治疗需要对分子机制有深入的了解.
- 表观遗传修饰,特别是甲基化,在心血管疾病的发病过程中越来越多地被发现.
研究的目的:
- 审查DNA,蛋白质和RNAN6 - 甲基氨酸 (m6A) 甲基化的生物过程.
- 总结这些甲基化修饰在主要心血管疾病中的作用.
- 突出表观遗传机制作为心血管疾病的治疗和诊断点的潜力.
主要方法:
- 对表观遗传学研究近期进展的文献综述.
- 专注于甲基化修饰:DNA甲基化,蛋白质甲基化和m6ARNA修饰.
- 综合与心血管疾病相关的发现,包括心脏缩,心力衰竭,缺血性心脏病和动脉样硬化.
主要成果:
- 甲基化修改显著影响与心血管健康相关的基因表达.
- 确定了DNA,蛋白质和m6A甲基化在心脏缩,心力衰竭,缺血性心脏病和动脉样硬化中的特定作用.
- 表观遗传改变与各种心血管疾病的进展和发病有关.
结论:
- 表观遗传甲基化修饰是心血管疾病发展和进展的组成部分.
- 针对这些甲基化机制为心脏病学中的新型诊断和治疗策略提供了有希望的途径.
- 对表观遗传调制的进一步研究对于推进心血管医学至关重要.
相关概念视频
01:37Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
01:46Epigenetic Regulation
33.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.4K
01:17Phase II Reactions: Methylation Reactions
655
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
655
01:30Coronary Artery Disease I: Introduction
846
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
846
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516
01:26Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291